Literature DB >> 23846804

HMG-CoA reductase inhibitors, simvastatin and atorvastatin, downregulate ABCG1-mediated cholesterol efflux in human macrophages.

Wei Wang1, Wei Song, Yu Wang, Lianfeng Chen, Xiaowei Yan.   

Abstract

Recent studies showed that statins reduce ATP-binding cassette transporter A1 expression and ATP-binding cassette transporter A1-mediated cholesterol efflux in macrophages, whereas the effect of statins on ATP-binding cassette transporter G1 (ABCG1), another important lipid transporter, is still unclear. Here, we investigated the expression and functionality of ABCG1 on statins in THP-1-derived macrophages and human peripheral blood mononuclear cells. Simvastatin and atorvastatin were used in this study. Treatment with statins significantly decreased ABCG1-mediated cholesterol efflux in human macrophages (from 33.8% ± 2.8% of control to 22.9% ± 1.7% of 10 µM simvastatin or to 23.3% ± 3.3% of 10 µM atorvastatin; P < 0.01, n = 4), whereas the protein expression of ABCG1 remained unaltered on statins. Further analysis revealed that 2 major ABCG1 isoforms responded to statins differently. The expression of ABCG1-S, which exhibited higher activity in cholesterol efflux than ABCG1-L, was significantly decreased on statins compared with increased expression of ABCG1-L. The results suggested that the proportion change of ABCG1 isoform expressions could contribute to reduced ABCG1 functionality under treatment with statins. The effects of statins on ABCG1 isoform expression and functionality were reversed by low-dose liver X receptor agonist, TO-901317, indicating that statins' downregulation of ABCG1 functionality was likely through liver X receptor-dependent pathway. In conclusion, simvastatin and atorvastatin decreased ABCG1-mediated cholesterol efflux in human macrophages without alteration of total ABCG1 protein level. The proportion change of ABCG1 isoforms expressions may be involved in the down-regulation of ABCG1 functionality by statins, which provided a novel mechanism for the regulation of ABCG1 activity.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23846804     DOI: 10.1097/FJC.0b013e3182927e7c

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  12 in total

1.  High-Density Lipoprotein (HDL) Phospholipid Content and Cholesterol Efflux Capacity Are Reduced in Patients With Very High HDL Cholesterol and Coronary Disease.

Authors:  Anandita P Agarwala; Amrith Rodrigues; Marjorie Risman; Mary McCoy; Kevin Trindade; Liming Qu; Marina Cuchel; Jeffrey Billheimer; Daniel J Rader
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-04-02       Impact factor: 8.311

2.  Atorvastatin and trans-caryophyllene for the prevention of leukopenia in an experimental chemotherapy model in Wistar rats.

Authors:  Maria Ines Campos; Wellington Dorigheto Andrade Vieira; Celso Neiva Campos; Fernando Monteiro Aarestrup; Beatriz Julião Vieira Aarestrup
Journal:  Mol Clin Oncol       Date:  2015-04-09

Review 3.  Nature and nurture in atherosclerosis: The roles of acylcarnitine and cell membrane-fatty acid intermediates.

Authors:  Harry C Blair; Jorge Sepulveda; Dionysios J Papachristou
Journal:  Vascul Pharmacol       Date:  2015-06-30       Impact factor: 5.773

Review 4.  Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.

Authors:  Behzad Yeganeh; Emilia Wiechec; Sudharsana R Ande; Pawan Sharma; Adel Rezaei Moghadam; Martin Post; Darren H Freed; Mohammad Hashemi; Shahla Shojaei; Amir A Zeki; Saeid Ghavami
Journal:  Pharmacol Ther       Date:  2014-02-26       Impact factor: 12.310

Review 5.  Current and future therapies for addressing the effects of inflammation on HDL cholesterol metabolism.

Authors:  Fatima Iqbal; Wendy S Baker; Madiha I Khan; Shwetha Thukuntla; Kevin H McKinney; Nicola Abate; Demidmaa Tuvdendorj
Journal:  Br J Pharmacol       Date:  2017-03-23       Impact factor: 8.739

6.  The implication of cigarette smoking and cessation on macrophage cholesterol efflux in coronary artery disease patients.

Authors:  Wei Song; Wei Wang; Li-Yang Dou; Yu Wang; Yan Xu; Lian-Feng Chen; Xiao-Wei Yan
Journal:  J Lipid Res       Date:  2015-01-19       Impact factor: 5.922

7.  Combined use of metformin and atorvastatin attenuates atherosclerosis in rabbits fed a high-cholesterol diet.

Authors:  Fei Luo; Yuan Guo; Gui-Yun Ruan; Jun-Ke Long; Xi-Long Zheng; Qin Xia; Shui-Ping Zhao; Dao-Quan Peng; Zhen-Fei Fang; Xiang-Ping Li
Journal:  Sci Rep       Date:  2017-05-19       Impact factor: 4.379

8.  Combined Effect of Diosgenin Along with Ezetimibe or Atorvastatin on the Fate of Labelled Bile Acid and Cholesterol in Hypercholesterolemic Rats.

Authors:  Alejandro Marín-Medina; Gonzalo Ruíz-Hidalgo; Jorge L Blé-Castillo; Alma M Zetina-Esquivel; Rodrigo Miranda Zamora; Isela E Juárez-Rojop; Juan C Díaz-Zagoya
Journal:  Int J Environ Res Public Health       Date:  2019-02-20       Impact factor: 3.390

9.  ABCG1 rs57137919G>a polymorphism is functionally associated with varying gene expression and apoptosis of macrophages.

Authors:  Fang Liu; Wei Wang; Yan Xu; Yu Wang; Lian-Feng Chen; Quan Fang; Xiao-Wei Yan
Journal:  PLoS One       Date:  2014-06-27       Impact factor: 3.240

10.  Simvastatin promotes NPC1-mediated free cholesterol efflux from lysosomes through CYP7A1/LXRα signalling pathway in oxLDL-loaded macrophages.

Authors:  Xiaoyang Xu; Aolin Zhang; Matthew S Halquist; Xinxu Yuan; Scott C Henderson; William L Dewey; Pin-Lan Li; Ningjun Li; Fan Zhang
Journal:  J Cell Mol Med       Date:  2016-09-15       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.